Clinical Trials Directory

Trials / Sponsors / Bio-innova Co., Ltd

Bio-innova Co., Ltd

Industry · 16 registered clinical trials.

StatusTrialPhaseStarted
UnknownSildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets
Healthy Subjects
Phase 12025-02-04
UnknownEsomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition
Healthy Subjects
Phase 12024-10-01
UnknownDutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
Healthy Subjects
Phase 12024-09-24
UnknownVildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
Healthy Subjects
Phase 12024-09-05
UnknownFebuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
Healthy Subjects
Phase 12024-09-03
UnknownEsomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition
Healthy Subjects
Phase 12024-08-29
UnknownDapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg
Healthy Subjects
Phase 12024-07-23
UnknownDesogestrel Tablets (0.075 mg) Relative to Originator Desogestrel Tablets (0.075 mg)
Healthy Subjects
Phase 12024-07-16
UnknownNebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg
Healthy Subjects
Phase 12024-07-09
UnknownTicagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
Healthy Subjects
Phase 12024-06-18
UnknownSitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Healthy Subjects
Phase 12024-06-04
UnknownSacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablet
Healthy Subjects
Phase 12024-05-06
UnknownSitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Healthy Subjects
Phase 12024-04-30
UnknownDrospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®
Healthy Subjects
Phase 12024-03-05
UnknownEmpagliflozin 10 mg Tablets Relative to Jardiance 10 mg
Healthy Subjects
Phase 12024-02-27
UnknownDrospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
Healthy Subjects
Phase 12024-02-13